Patents Assigned to Millennium Pharmaceuticals, Inc.
  • Crystalline form of a proteasome inhibitor
    Patent number: 10072029
    Abstract: The present disclosure relates to a novel crystalline form of a proteasome inhibitor, and to the processes for the preparation thereof. The novel crystalline form according to the disclosure may be used in the preparation of pharmaceutical compositions for the treatment of cancer.
    Type: Grant
    Filed: February 10, 2016
    Date of Patent: September 11, 2018
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Marianne Langston, Debra Mazaik, Eric Elliott, Anton Peterson, Patricia Andres, Jing Teng
  • Pharmaceutical Formulation of an Anti-Guanylyl Cyclase C Antibody Conjugate Comprising Histidine or a Salt Thereof and Polysorbate 20
    Publication number: 20180243439
    Abstract: Provided is a formulation containing an immunoconjugate comprising an anti-GCC antibody molecule and a therapeutic agent, which is superior in stability and useful as a prophylactic or therapeutic agent for gastrointestinal cancer and the like. A formulation comprising (i) an immunoconjugate of the following formula (I): wherein Ab is an anti-GCC antibody molecule, X is a linker component, Z is a therapeutic agent, and m is an integer from 1-15, or a pharmaceutically acceptable salt thereof, (ii) polysorbate 20, and (iii) histidine or a salt thereof.
    Type: Application
    Filed: April 23, 2015
    Publication date: August 30, 2018
    Applicant: MILLENNIUM PHARMACEUTICALS, INC.
    Inventors: Shohei HORIUCHI, Tomomi SATO
  • Formulation for anti-?4?7 antibody
    Patent number: 10040855
    Abstract: Antibody formulations are described comprising a mixture of an anti-?4?7 antibody, an antioxidant or chelator, and at least one free amino acid. The disclosed formulations may have improved stability, reduced aggregate formation, or both. The present invention further provides a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-?4?7 antibody in vivo.
    Type: Grant
    Filed: May 2, 2012
    Date of Patent: August 7, 2018
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Willow Diluzio, Phoung M. Nguyen, Csanad M. Varga, Vaithianathan Palaniappan, Jason Brown
  • Derivatives of 1-amino-2-cyclobutylethylboronic acid
    Patent number: 10035811
    Abstract: The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.
    Type: Grant
    Filed: August 18, 2017
    Date of Patent: July 31, 2018
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Paul E. Fleming, Jing Li
  • Crystalline forms of sodium 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido [5,4-D][2]benzazepin-2-YL]amino}-2-methoxybenzoate
    Patent number: 10017513
    Abstract: The present invention is directed to a compound of formula (I): or a crystalline form thereof, or a solvate thereof; to a solid pharmaceutical composition comprising a pharmaceutically effective amount of the compound of formula (I), or a crystalline form thereof, or a solvate thereof, and at least one pharmaceutically acceptable carrier or diluent, and to the use of a compound of formula (I), or a crystalline form thereof, or a solvate thereof, for treating a patient suffering from, or subject to, a disease, disorder, or condition mediated by Aurora kinase, and methods related thereto.
    Type: Grant
    Filed: October 13, 2016
    Date of Patent: July 10, 2018
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Ian Armitage, Martin I. Cooper, Mark D. Eddleston, Neil C. Faiber, Quentin J. McCubbin, Stephen W. Watt
  • Methods of treating ulcerative colitis
    Patent number: 10004808
    Abstract: Methods for inducing clinical remission of ulcerative colitis in a human patient are described comprising administration of an antibody that has binding specificity for human ?4?7 integrin using a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-?4?7 antibody in vivo.
    Type: Grant
    Filed: July 20, 2016
    Date of Patent: June 26, 2018
    Assignee: MILLENNIUM PHARMACEUTICALS, INC.
    Inventors: Irving H. Fox, Catherine Scholz
  • Synthesis of boronic ester and acid compounds
    Patent number: 10000529
    Abstract: The invention relates to the synthesis of boronic ester and acid compounds. More particularly, the invention provides improved synthetic processes for the large-scale production of boronic ester and acid compounds, including the peptide boronic acid proteasome inhibitor bortezomib.
    Type: Grant
    Filed: September 22, 2017
    Date of Patent: June 19, 2018
  • Aurora kinase inhibitors for inhibiting mitotic progression
    Patent number: 9988384
    Abstract: The present invention relates to compounds and methods for the treatment of cancer. In particular, the invention provides potent inhibitors of Aurora A kinase, pharmaceutical compositions comprising the compounds, and methods of using the compounds for the treatment of cancer.
    Type: Grant
    Filed: August 25, 2011
    Date of Patent: June 5, 2018
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Christopher F. Claiborne, Todd B. Sells, Stephen G. Stroud
  • Heteroaryl compounds useful as inhibitors of SUMO activating enzyme
    Patent number: 9962386
    Abstract: Disclosed are chemical entities which are compounds of formula (I): or pharmaceutically acceptable salts thereof; wherein Y, Ra, Ra?, Rb, Rc, X1, X2, X3, Rd, Z1, and Z2 have the values described herein and stereochemical configurations depicted at asterisked positions indicate absolute stereochemistry. Chemical entities according to the disclosure can be useful as inhibitors of Sumo Activating Enzyme (SAE). Further provided are pharmaceutical compositions comprising a compound of the disclosure and methods of using the compositions in the treatment of proliferative, inflammatory, cardiovascular, and neurodegenerative diseases or disorders.
    Type: Grant
    Filed: April 17, 2017
    Date of Patent: May 8, 2018
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Matthew O. Duffey, Dylan England, Brian Scott Freeze, Zhigen Hu, Steven Langston, Charles McIntyre, Hirotake Mizutani, Koji Ono, He Xu
  • Methods for the identification, assessment, and treatment of patients with cancer therapy
    Patent number: 9963747
    Abstract: The present invention is directed to the identification of predictive markers that can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to treatment. In particular, the present invention is directed to the use of certain individual and/or combinations of predictive markers, wherein the expression of the predictive markers correlates with responsiveness or non-responsiveness to a therapeutic regimen. Thus, by examining the expression levels of individual predictive markers and/or predictive markers comprising a marker set, it is possible to determine whether a therapeutic agent, or combination of agents, will be most likely to reduce the growth rate of tumors in a clinical setting.
    Type: Grant
    Filed: October 17, 2014
    Date of Patent: May 8, 2018
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Barbara M. Bryant, Andrew I. Damokosh, George J. Mulligan
  • Antibodies that bind OV064 and methods of use therefor
    Patent number: 9926378
    Abstract: Antibodies and antigen-binding fragments of antibodies that bind OV064 are disclosed. The antibodies bind an extracellular domain of OV064. Some of the antibodies and antigen-binding fragments bind an epitope on OV064 sufficient to induce internalization. In some embodiments, the antibodies are humanized, chimeric or human. Nucleic acids and vectors encoding the antibodies or portions thereof, recombinant cells that contain the nucleic acids, and compositions comprising the antibodies or antigen-binding fragments are also disclosed. The invention also provides therapeutic and diagnostic methods utilizing the antibodies and antigen-binding fragments provided herein.
    Type: Grant
    Filed: July 21, 2016
    Date of Patent: March 27, 2018
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Ole Petter Veiby, John S. Babcook
  • Biomarkers of response to proteasome inhibitors
    Patent number: 9920373
    Abstract: Disclosed are markers associated with sensitivity to treatment with proteasome inhibitors. Sensitivity is observed when RAS gene is wild type in tumor cells. Compositions and methods are further provided to assess markers of marker genes to predict outcome of treatment using proteasome inhibitors to patients having a solid tumor, such as a lung tumor or a colon tumor.
    Type: Grant
    Filed: November 9, 2012
    Date of Patent: March 20, 2018
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Allison Berger, Nibedita Chattopadhyay, Erik M. Koenig
  • Substituted pyrimidines for inhibiting Raf kinase activity
    Patent number: 9920048
    Abstract: The present invention provides methods of inhibiting Raf kinase activity in a patient, the method comprising administering to the patient a compound having formula I: or a pharmaceutically acceptable salt thereof, wherein Rx, Ry, R1, L1, L2, Cy1, and Cy2 are as defined as set forth in the specification.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: March 20, 2018
    Assignees: Millennium Pharmaceuticals, Inc., Sunesis Pharmaceuticals, Inc.
    Inventors: Weirong Chen, Jennifer Cossrow, Lloyd Franklin, Bing Guan, John Howard Jones, Gnanasambandam Kumaravel, Benjamin Lane, Adam Littke, Alexey Lugovskoy, Hairuo Peng, Noel Powell, Brian C. Raimundo, Hiroko Tanaka, Jeffrey Vessels, Thomas Wynn, Zhili Xin
  • METHOD OF TREATING PRIMARY SCLEROSING CHOLANGITIS
    Publication number: 20180051086
    Abstract: Disclosed is a method for treating a subject having primary sclerosing cholangitis, comprising administering to said subject an effective amount of a humanized antibody or antigen-binding fragment thereof having binding specificity for alpha 4 beta 7 integrin.
    Type: Application
    Filed: March 4, 2016
    Publication date: February 22, 2018
    Applicants: Takeda Development Centre Europe Ltd., Takeda Pharmaceutical Company Limited, Millennium Pharmaceuticals, Inc.
    Inventor: Brihad ABHYANKAR
  • Methods of treatment using pyridinonyl PDK1 inhibitors
    Patent number: 9873693
    Abstract: The present invention provides pyridinonyl PDK1 inhibitors and methods of treating cancer using the same.
    Type: Grant
    Filed: July 10, 2014
    Date of Patent: January 23, 2018
    Assignees: Sunesis Pharmaceuticals, Inc., Millennium Pharmaceuticals, Inc.
    Inventors: Kenneth Egnard Lind, Kathy Cao, Edward Yin-shiang Lin, Thinh Ba Nguyen, Bradley T. Tangonan, Daniel A. Erlanson, Kevin Guckian, Robert Lowell Simmons, Wen-cherng Lee, Lihong Sun, Stig Hansen, Nuzhat Pathan, Lei Zhang
  • Synthesis of boronic ester and acid compounds
    Patent number: 9862745
    Abstract: The invention relates to the synthesis of boronic ester and acid compounds. More particularly, the invention provides improved synthetic processes for the large-scale production of boronic ester and acid compounds, including the peptide boronic acid proteasome inhibitor bortezomib.
    Type: Grant
    Filed: January 8, 2016
    Date of Patent: January 9, 2018
  • Inhibitors of NEDD8-activating enzyme
    Patent number: 9850214
    Abstract: Disclosed are chemical entities which are inhibitors of Nedd8-activating enzyme (NAE), namely, the compound {(1S,2S,4R)-4-[(6-{[(1R,2S)-5-chloro-2-methoxy-2,3-dihydro-1H-inden-1-yl]amino}pyrimidin-4-yl)oxy]-2-hydroxycyclopentyl}methyl sulfamate and pharmaceutically acceptable salts thereof; solid state forms thereof; and prodrugs thereof. Also disclosed are methods of using the chemical entities to treat disorders such as cancer.
    Type: Grant
    Filed: July 8, 2014
    Date of Patent: December 26, 2017
    Assignee: MILLENNIUM PHARMACEUTICALS, INC.
    Inventors: Ashley Sue McCarron, Todd B. Sells, Matthew Stirling, Stephen G. Stroud
  • Molecules of the card-related protein family and uses thereof
    Patent number: 9828590
    Abstract: Novel CARD-9, CARD-10, or CARD-11 polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated CARD-9, CARD-10, or CARD-11 proteins, the invention further provides CARD-9, CARD-10, or CARD-11, fusion proteins, antigenic peptides and anti-CARD-9, CARD-10, or CARD-11 antibodies. The invention also provides CARD-9, CARD-10, or CARD-11 nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which a CARD-9, CARD-10, or CARD-11 gene has been introduced or disrupted. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: June 17, 2015
    Date of Patent: November 28, 2017
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventor: John Bertin
  • Biomarkers of response to NAE inhibitors
    Patent number: 9827246
    Abstract: Disclosed herein are markers whose mutational status is associated with sensitivity to treatment with NAE inhibitors. Mutational status is determined by measurement of characteristics of markers associated with the marker genes. Compositions and methods are provided to assess markers of marker genes to predict response to NAE inhibition treatment.
    Type: Grant
    Filed: October 26, 2012
    Date of Patent: November 28, 2017
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Stephen J. Blakemore, Bin Li, George J. Mulligan, Matthew C. Schu, Peter G. Smith
  • Vedolizumab for the Treatment of Fistulizing Crohn's Disease
    Publication number: 20170327584
    Abstract: A method for treating a human patient suffering from fistulizing Crohn's disease, comprising administering to a patient suffering from fistulizing Crohn's disease, a humanized antibody having binding specificity for human ?4?7 integrin, wherein the human patient has a seton that was surgically placed prior to administration of the antibody, and wherein the dosing regimen induces fistula(e) healing.
    Type: Application
    Filed: November 25, 2015
    Publication date: November 16, 2017
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventor: Karen L. Lasch